Please login to the form below

Not currently logged in

Gilead owes BMS millions after losing Yescarta patent infringement trial

Jury found Gilead's CAR-T infringed on exclusive patent


Bristol-Myers Squibb has proved its case for suing Gilead over the alleged patent infringement of its CAR-T therapy Yescarta, winning $752m in the effort. 

Gilead has been ordered to pay BMS $585m in damages, plus a 27.6% running royalty on all sales of Yescarta (axicabtagene ciloleucel).

The basis of the lawsuit is that Yescarta, which is marketed by Gilead’s Kite Pharma division, infringed on a patent licensed by BMS’ Juno Therapeutics from Sloan Kettering and the Memorial Sloan Kettering Cancer Center for the exclusive rights to the technology.

It alleged that Kite scientists copied research from the scientists at Sloan Kettering to advance their own CAR-T development, which then lead to the approval of Yescarta.

In CAR-T therapies, patients’ cells are harvested and modified so they are more likely to seek out and destroy cancer cells expressing a particular antigen. Once reprogrammed, the T cells are infused back into the patient in order to fight the cancer.

Yescarta has been slow to growth, bringing in $183m in the first nine months of the year from its use in diffuse large B-cell lymphoma and other B-cell lymphoma types.

In a statement, Gilead said it steadfastly disagreed with the decision.

"We remain steadfast in our opinion that Sloan Kettering's patent is not infringed and is invalid," it said.

"Given that Kite independently developed Yescarta and assumed all of the risk in its discovery and development, we do not believe Sloan Kettering and Juno are entitled to any level of damages."

BMS will be especially pleased with the verdict, given that it has recently announced a positive phase 1 trial of its liso-cel (lisocabtagene maraleucel) CAR-T therapy.

The efficacy data looks similar on paper to the two approved CAR-T therapies – Yescarta and Novartis’ Kymriah (tisagenlecleucel). It was studied, however, in a much larger group of patients, and BMS is also hoping to compensate for late entry with a strong safety profile.

BMS acquired liso-cel from its $6bn takeover of Celgene – prior to being acquired, Celgene had put the CAR-T at becoming a potentially $3bn product.

Gaining approval for liso-cel is a critical compenent on the payout of BMS’ takeover of Celgene, and is one of three drugs tied to the CVR payments. To qualify, it will have to secure FDA approval by the end of next year.

Article by
Lucy Parsons

16th December 2019

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....